4/8/2019 | BKCVHY | S&P upgrades Horizon
|
3/18/2019 | HYLM | Horizon Pharma pays down term loans, plans to repay 6 5/8% notes
|
3/18/2019 | BK | Horizon Pharma pays down term loans, plans to repay 6 5/8% notes
|
3/11/2019 | BK | Horizon Pharma USA gets $200 million of new revolving commitments
|
3/6/2019 | BKHY | S&P puts Horizon Pharma on positive watch
|
2/28/2019 | CV | Market Commentary: LivePerson oversubscribed, expands on debut; Applied Optoelectronics eyed; Novavax tanks
|
8/8/2018 | CV | Market Commentary: Market eyes Rapid7, NII Holdings; Tesla dominates; Horizon on the rise
|
3/14/2018 | SP | New Issue: Credit Suisse sells $2 million ARES linked to basket of 10 stocks
|
3/13/2018 | SP | New Issue: Credit Suisse sells $2.79 million accelerated return notes on 10 stocks
|
3/7/2018 | SP | Credit Suisse plans 18-month ARES linked to basket of 10 stocks
|
3/7/2018 | SP | Credit Suisse to price 18-month ARES linked to basket of 10 stocks
|
11/27/2017 | CV | Market Commentary: Square tumbles after record high, health care companies active in post-holiday lull
|
10/6/2017 | BK | Horizon Pharma sets Tuesday morning lender call, Citigroup to lead deal
|
5/8/2017 | CV | Market Commentary: DexCom, Kaman, Becton Dickinson enter market; Horizon falters as guidance lowered; Cobalt up
|
5/8/2017 | CV | Market Commentary: Morning Commentary: DexCom, Kaman, Becton Dickinson plan to tap market; Horizon falters
|
11/22/2016 | SP | New Issue: Morgan Stanley prices $6.24 million trigger participation notes linked to 45 stocks
|
10/25/2016 | HY | Market Commentary: Sprint, T-Mobile see some movement; new Netflix, URI trade; communications ride AT&T takeover talks
|
10/19/2016 | HY | Market Commentary: NGL Energy, Horizon Pharma price; new NGL notes jump; Sprint on tap; coal names catch fire
|
10/19/2016 | BKCVDDEMIGPV | Market Commentary: NGL Energy, Horizon deals price; new NGL notes jump; Sprint on tap; coal names catch fire
|
10/19/2016 | HY | New Issue: Horizon Pharma prices $300 million eight-year notes at par to yield 8ľ%
|
10/14/2016 | HY | Market Commentary: Primary quiet to close out $770 million week; UCP slates deal; Lions Gate, Warner continue rise
|
10/14/2016 | BKCVDDEMIGPV | Market Commentary: Primary quiet to close out $770 million week; UCP slates deal; Lions Gate, Warner continue rise
|
10/13/2016 | HY | Market Commentary: Warner Music, Lions Gate price, gain; Horizon shops deal; Rackspace rises; funds lose $72 million
|
10/13/2016 | BKCVDDEMIGPV | Market Commentary: Warner Music, Lions Gate price, gain; Horizon shops deal; Rackspace rises; funds lose $72 million
|
10/13/2016 | CLHY | Market Commentary: Confie Seguros, Platform Specialty, Guggenheim Partners, ConvergeOne, Lions Gate break
|
10/13/2016 | BK | Market Commentary: Confie Seguros, Platform Specialty, Guggenheim Partners, ConvergeOne, Lions Gate break
|
10/13/2016 | BK | Horizon Pharma talks $375 million term loan at Libor plus 400-425 bps
|
10/13/2016 | HY | Market Commentary: Morning Commentary: Junk lower amid weaker equities; Warner Music euro tranche prices tight
|
10/13/2016 | HY | Horizon Pharma starts roadshow for $300 million eight-year notes; initial guidance 8˝%
|
10/11/2016 | CLHY | Market Commentary: Rocket Software, Harbortouch, Intrawest Operations break; Confie Seguros reveals changes
|
10/11/2016 | BK | Market Commentary: Rocket Software, Harbortouch, Intrawest Operations break; Confie Seguros reveals changes
|
10/11/2016 | BK | Horizon Pharma plans to launch new loan deal on Thursday
|
9/26/2016 | BK | Horizon Pharma adds Citi to arranger group on $675 million term loan
|
9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
9/12/2016 | BK | Horizon Pharma plans $675 million in term loans for Raptor purchase
|
9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
7/1/2016 | CV | Market Commentary: Convertibles quiet ahead of holiday; Exelixis in line; Softbank/Alibaba mandatories better
|
5/12/2016 | PP | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
5/12/2016 | CV | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
5/12/2016 | CV | Market Commentary: Morning Commentary: Qihoo 360 convertibles, shares ease; Horizon Pharma, Jazz bonds down
|
5/9/2016 | PP | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
5/9/2016 | CV | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
4/13/2016 | DD | Market Commentary: Distressed energy debt rallies on output cut hopes, oil price boost; healthcare converts underperform
|
4/12/2016 | HY | Market Commentary: Distressed energy debt rallies on output cut hopes; healthcare convertibles underperform
|
4/12/2016 | PP | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
4/7/2016 | PP | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
3/15/2016 | PP | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
3/15/2016 | CV | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
3/7/2016 | SP | New Issue: Bank of America prices $2.2 million enhanced return notes on 10 stocks
|
2/29/2016 | PP | Market Commentary: Horizon Pharma contracts as shares drop; Priceline adds in line; Newmont expands slightly
|
2/29/2016 | CV | Market Commentary: Horizon Pharma contracts as shares drop; Priceline adds in line; Newmont expands slightly
|
2/29/2016 | SP | Bank of America to price enhanced return notes linked to 10 stocks
|
2/29/2016 | CV | Market Commentary: Morning Commentary: Priceline adds in line; Newmont expands; Horizon contracts as shares drop
|
12/11/2015 | PP | Market Commentary: Convertibles down in line with lower equities; Horizon Pharma falters; SunEdison steady
|
12/11/2015 | CV | Market Commentary: Convertibles down in line with lower equities; Horizon Pharma falters; SunEdison steady
|
12/3/2015 | BKBWCVHYLW | Horizon Pharma has 4.6x leverage, could go to 6x for right opportunity
|
11/11/2015 | CV | Market Commentary: Aceto flat to lower outright, adds on swap; SunEdison extends slide; Horizon Pharma drops
|
11/9/2015 | PP | Market Commentary: Iconix, Horizon Pharma regain ground after steep losses; Priceline 1% expands on swap
|
11/9/2015 | CV | Market Commentary: Iconix, Horizon Pharma regain ground after steep losses; Priceline 1% expands on swap
|
11/6/2015 | PP | Market Commentary: Iconix Brand collapses on accounting restatements, lowered guidance; HomeAway drops back
|
11/6/2015 | CV | Market Commentary: Iconix Brand collapses on accounting restatements, lowered guidance; HomeAway drops back
|
10/24/2015 | DD | Market Commentary: Valeant leads pharma rebound; Platform Specialty off as CEO plans exit; energy names slide
|
10/23/2015 | HY | Market Commentary: Valeant leads pharma rebound; Platform Specialty off as CEO plans exit; energy names slide
|
10/23/2015 | PP | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
10/23/2015 | CV | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
10/23/2015 | CV | Market Commentary: Morning Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings
|
10/23/2015 | DD | Market Commentary: Valeant, other drug makers continue slide; hospital names trade off; oil credits again lower
|
10/22/2015 | HY | Market Commentary: Valeant, other drug makers continue slide; hospital names trade off; energy credits lower
|
10/22/2015 | PP | Market Commentary: Intel’s 2.95% convertible sees outright sellers; Proofpoint sees better buyers on earnings
|
10/22/2015 | CV | Market Commentary: Intel’s 2.95% convertible sees outright sellers; Proofpoint sees better buyers on earnings
|
10/22/2015 | CV | Market Commentary: Morning Commentary: Horizon Pharma lower again; valuations steady; Proofpoint sees better buyers
|
10/22/2015 | DD | Market Commentary: Valeant debt clobbered as report alleges fraud; other pharmaceuticals fall; oil credits lower
|
10/21/2015 | HY | Market Commentary: Valeant clobbered as report alleges fraud; other pharmaceuticals fall; oil credits lower
|
10/21/2015 | PP | Market Commentary: SanDisk lower on swap after takeout news; Micron lower outright; Horizon slumps on swap
|
10/21/2015 | CV | Market Commentary: SanDisk lower on swap after takeout news; Micron lower outright; Horizon slumps on swap
|
10/21/2015 | DD | Market Commentary: Valeant bonds shed Monday gains; Horizon Pharma converts slide; AMD firm despite downgrade
|
10/20/2015 | HY | Market Commentary: Valeant bonds shed Monday gains; Horizon Pharma converts slide; AMD firm despite downgrade
|
10/20/2015 | PP | Market Commentary: SanDisk 0.5% contracts on swap as SanDisk 1.5% rides higher; Horizon Pharma, Tesla drop
|
10/20/2015 | CV | Market Commentary: SanDisk 0.5% contracts on swap as SanDisk 1.5% rides higher; Horizon Pharma, Tesla drop
|
9/29/2015 | PP | Market Commentary: Convertibles improve; Horizon Pharma paper weakens amid Depomed battle; Chesapeake lower
|
9/29/2015 | CV | Market Commentary: Convertibles improve; Horizon Pharma paper weakens amid Depomed battle; Chesapeake lower
|
9/29/2015 | CV | Market Commentary: Morning Commentary: Convertibles head to higher ground; Horizon paper weakens amid Depomed battle
|
9/22/2015 | PP | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
9/22/2015 | CV | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
7/20/2015 | PP | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
7/20/2015 | CV | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
7/7/2015 | PP | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
7/7/2015 | CV | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
7/7/2015 | CV | Market Commentary: Morning Commentary: Medicines convertibles higher in active trade; Depomed deflects Horizon offer
|
6/11/2015 | SP | New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
|
6/4/2015 | CV | Market Commentary: Rate-sensitive convertible notes under pressure; Frontier Communications, Anadarko on tap
|
4/23/2015 | CLHY | Market Commentary: Charter term G dips with acquisition worries; DJO Finance, Horizon Pharma changes emerge
|
4/23/2015 | BK | Market Commentary: Charter term G dips with acquisition worries; DJO Finance, Horizon Pharma changes emerge
|
4/23/2015 | BK | Horizon Pharma cuts term loan B to $400 million, reduces pricing
|
4/21/2015 | BKCVHY | S&P: Horizon Pharma loan BB-, notes B-, convertibles CCC+
|
4/20/2015 | CLHY | Market Commentary: TGI Friday’s breaks; Staples, Kloeckner revised; Horizon Pharma, Intrawest, Talbots set talk
|
4/20/2015 | BK | Market Commentary: TGI Friday’s breaks; Staples, Kloeckner revised; Horizon Pharma, Intrawest, Talbots set talk
|
4/20/2015 | BK | Horizon Pharma launches $500 million term loan B to investors
|
4/16/2015 | CV | Market Commentary: SanDisk lower outright, edges up on swap; Teva below parity; planned Pernix looks cheap
|
4/13/2015 | BKHY | Horizon’s revised financing to include $800 million of loans, notes
|
4/13/2015 | PP | Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
|
4/13/2015 | CV | Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
|
3/31/2015 | BK | Horizon Pharma outlines terms on $900 million term loan B commitment
|
3/30/2015 | PP | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
3/30/2015 | CV | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
3/30/2015 | CV | Market Commentary: Morning Commentary: Horizon Pharma jumps outright; health care bid remains strong; Intel active
|
3/30/2015 | BKHY | Horizon Pharma gets $900 million debt commitment for Hyperion purchase
|
3/19/2015 | CV | Market Commentary: Tesla Motors up in active trade; Chesapeake mostly quiet with shares down; primary stays hushed
|
3/16/2015 | CVLM | Horizon Pharma to exchange $32.2 million more notes for stock, cash
|
3/13/2015 | CV | Horizon Pharma greenshoe lifts 2.5% exchangeables to $400 million
|
3/6/2015 | PP | Market Commentary: New convertibles from Horizon Phama, Consolidated-Tamoka, InterDigital expand on swap
|
3/6/2015 | CV | Market Commentary: New convertibles from Horizon Phama, Consolidated-Tamoka, InterDigital expand on swap
|
3/6/2015 | CV | Market Commentary: Morning Commentary: New Horizon, Consolidated deals up 2 points on hedge; new InterDigital gains
|
3/6/2015 | CV | New Issue: Horizon Pharma prices upsized $350 million seven-year exchangeables at 2.5%, up 37.5%
|
3/5/2015 | PP | Market Commentary: NXP Semiconductors expands; Cheniere extends gains; Horizon Pharma deal looks ‘cheap’
|
3/5/2015 | CV | Market Commentary: NXP Semiconductors expands; Cheniere extends gains; Horizon Pharma deal looks ‘cheap’
|
3/5/2015 | CV | Market Commentary: Morning Commentary: Cheniere extends gains; planned Horizon Pharma deal looks ‘cheap’
|
3/4/2015 | PP | Market Commentary: Cheniere expands on hedge; new Gogo upsized, trades flattish; three deals join calendar
|
3/4/2015 | CV | Market Commentary: Cheniere expands on hedge; new Gogo upsized, trades flattish; three deals join calendar
|
3/4/2015 | CV | Horizon Pharma offers $300 million seven-year exchangeables at 2.25%-2.75%, up 27.5%-32.5%
|
12/15/2014 | CVLM | Horizon Pharma to exchange $11 million more notes for stock, cash
|
11/26/2014 | CVLM | Horizon Pharma to settle $8.6 million converted notes in stock, cash
|
10/24/2014 | CVLM | Horizon Pharma to settle $60.9 million converted notes in stock, cash
|
9/19/2014 | BK | Horizon Pharma draws full $300 million under term loan for acquisition
|